320 related articles for article (PubMed ID: 25538178)
1. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Santoro A; Gebbia V; Pressiani T; Testa A; Personeni N; Arrivas Bajardi E; Foa P; Buonadonna A; Bencardino K; Barone C; Ferrari D; Zaniboni A; Tronconi MC; Cartenì G; Milella M; Comandone A; Ferrari S; Rimassa L
Ann Oncol; 2015 Mar; 26(3):542-7. PubMed ID: 25538178
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
[TBL] [Abstract][Full Text] [Related]
4. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G
BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008
[TBL] [Abstract][Full Text] [Related]
5. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Gridelli C; Novello S; Zilembo N; Luciani A; Favaretto AG; De Marinis F; Genestreti G; Crinò L; Grossi F; Caffo O; Ferraù F; Cruciani G; Brandes AA; Galetta D; Barni S; Fasola G; Cerea G; Ferrari S; Iannacone C; Ciardiello F
J Thorac Oncol; 2014 May; 9(5):733-7. PubMed ID: 24722160
[TBL] [Abstract][Full Text] [Related]
6. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
[TBL] [Abstract][Full Text] [Related]
10. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
20. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
